Alofisel - direct healthcare professional communication (DHPC)

darvadstrocel

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Alofisel (darvadstrocel): Withdrawal from the EU market as its clinical benefit is no longer demonstrated to justify its continued use

Key facts

• Medicine name:
  Alofisel
• Active substance:
  darvadstrocel
• Therapeutic area (MeSH):
  Rectal Fistula
• Regulatory outcome:
  Withdrawal
• DHPC type:
  Lack of effect
• Human ATC codes:
  L04
• Dissemination date:
  19/12/2024